Announced Date: 2023-10-20 (October 20, 2023)
Asset Name: HS-20089
Licensor: Hansoh Pharma (Hansoh) (China)
Licensee (Buyer): GSK plc （UK）
.
Asset Modality: Antibody-drug conjugate (ADC)
Asset Target: B7-H4 ，topoisomerase inhibitor (TOPOi) payload
Potential indication：gynaecologic cancer, ovarian and endometrial cancer , other solid tumours
Current Stage: phase I trials in China
Scope of Authority:
GSK will obtain exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) to progress clinical development and commercialisation of HS-20089.
.
Deal Detail:
Upfront payment of $0.85 million;
Milestone payments up to $1.475 billion;
Total up to $1.57 billion.
Additional royalties based on net sales in the licensed territories.
.
Link:
GSK enters exclusive license agreement with Hansoh for HS-20089
